Left lobe graft poses a potential risk of hepatic venous outflow obstruction in adult living donor liver transplantation

Toshihiro Kitajima, Toshimi Kaido, Taku Iida, Shintaro Yagi, Yasuhiro Fujimoto, Kohei Ogawa, Akira Mori, Hideaki Okajima, Rinpei Imamine, Toshiya Shibata, Shinji Uemoto – 19 January 2016 – Hepatic venous outflow obstruction (HVOO) is a critical complication after living donor liver transplantation (LDLT). This study aimed to evaluate the incidence of HVOO and the risk factors for HVOO in adults. From 2005 to 2015, 430 adult LDLT patients (right lobe [RL] graft, 270 patients; left lobe [LL] graft, 160 patients) were enrolled and divided into no HVOO (n = 413) and HVOO (n = 17) groups.

Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma

Elizabeth L. Yanik, Srinath Chinnakotla, Sally K. Gustafson, Jon J. Snyder, Ajay K. Israni, Dorry L. Segev, Eric A. Engels – 19 January 2016 – For recipients of liver transplantations (LTs) for hepatocellular carcinoma (HCC), HCC recurrence after transplantation remains a major concern. Sirolimus (SRL), an immunosuppressant with anticarcinogenic properties, may reduce HCC recurrence and improve survival. In our study, the US Scientific Registry of Transplant Recipients was linked to pharmacy claims.

Relevance of microRNA‐18a and microRNA‐199a‐5p to hepatocellular carcinoma recurrence after living donor liver transplantation

Kazutoyo Morita, Ken Shirabe, Akinobu Taketomi, Yuji Soejima, Tomoharu Yoshizumi, Hideaki Uchiyama, Toru Ikegami, Yo‐ichi Yamashita, Keishi Sugimachi, Norifumi Harimoto, Shinji Itoh, Tetsuo Ikeda, Yoshihiko Maehara – 19 January 2016 – There are few reports about recurrence‐related microRNAs (miRNAs) after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to identify novel recurrence‐related miRNAs after living donor liver transplantation (LDLT) for HCC.

Subscribe to